NASDAQ:VECT VectivBio Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding VectivBio Holding AG Please log in to your account or sign up in order to add this asset to your watchlist. $5.96 +0.09 (+1.53%) (As of 07/6/2022 12:00 AM ET) Add Compare Share Today's Range$5.94▼$6.0150-Day Range$4.20▼$6.5552-Week Range$2.74▼$11.00Volume7,297 shsAverage Volume23,203 shsMarket Capitalization$202.58 millionP/E RatioN/ADividend YieldN/APrice Target$23.00 ProfileAnalyst RatingsChartCompetitorsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media VectivBio MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside286.2% Upside$23.00 Price TargetShort InterestHealthy0.03% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.84Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($2.47) to ($2.48) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.1.87 out of 5 starsMedical Sector662nd out of 1,433 stocksBiological Products, Except Diagnostic Industry100th out of 220 stocks 3.5 Analyst's Opinion Consensus RatingVectivBio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $23.00, VectivBio has a forecasted upside of 286.2% from its current price of $5.96.Amount of Analyst CoverageVectivBio has only been the subject of 1 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.03% of the float of VectivBio has been sold short.Short Interest Ratio / Days to CoverVectivBio has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in VectivBio has recently increased by 34.38%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldVectivBio does not currently pay a dividend.Dividend GrowthVectivBio does not have a long track record of dividend growth. Previous Next 0.0 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for VECT. Previous Next 3.2 News and Social Media Coverage News SentimentVectivBio has a news sentiment score of 0.84. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for VectivBio this week, compared to 0 articles on an average week.Search Interest1 people have searched for VECT on MarketBeat in the last 30 days. MarketBeat Follows3 people have added VectivBio to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, VectivBio insiders have not sold or bought any company stock.Percentage Held by Institutions68.43% of the stock of VectivBio is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for VectivBio are expected to decrease in the coming year, from ($2.47) to ($2.48) per share.Price to Book Value per Share RatioVectivBio has a P/B Ratio of 1.75. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive VECT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for VectivBio and its competitors with MarketBeat's FREE daily newsletter. Email Address About VectivBioVectivBio Holding AG, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for treatments of severe rare conditions. It develops apraglutide, a long-acting synthetic peptide analog of glucagon-like peptide-2 that is in Phase III clinical trial for the treatment of patients with short bowel syndrome-intestinal failure (SBS-IF), as well as apraglutide is in Phase II clinical trial for SBS-IF in patients with colon-in-continuity anatomy. The company is also developing apraglutide, which is in Phase II clinical trial for patients with steroid-refractory gastrointestinal acute versus host disease (aGvHD). The company was incorporated in 2019 and is headquartered in Basel, Switzerland.Read More VECT Stock News HeadlinesJuly 5, 2022 | americanbankingnews.comVectivBio Holding AG (NASDAQ:VECT) Sees Large Growth in Short InterestJuly 1, 2022 | seekingalpha.comVectivBio Holding rallies after Piper Sandler initiates Bull rating on biopharma stockJuly 7, 2022 | Investing Daily (Ad)27 U.S. Cities Where Stocks Yield 26% a YearWhat’s the highest-yielding stock you’ve ever owned? The dividends for these stocks have risen so fast over the years that they’re now yielding us an average of 26%! When you start getting paid 26% on your money, your financial problems tend to pretty much evaporate. July 1, 2022 | americanbankingnews.comVectivBio (NASDAQ:VECT) Now Covered by Analysts at Piper SandlerJune 29, 2022 | finance.yahoo.comVectivBio Announces Closing of $54 Million Aggregate FinancingJune 15, 2022 | marketwatch.comVectivBio Shares Drop 16% After Public Offering PricesJune 15, 2022 | seekingalpha.comVectivBio prices $30M follow-on stock offeringJune 15, 2022 | nasdaq.comVectivBio Says Combined Proceeds From Public Offering And Private Sale Total $50 MlnJuly 7, 2022 | Investing Daily (Ad)27 U.S. Cities Where Stocks Yield 26% a YearWhat’s the highest-yielding stock you’ve ever owned? The dividends for these stocks have risen so fast over the years that they’re now yielding us an average of 26%! When you start getting paid 26% on your money, your financial problems tend to pretty much evaporate. June 15, 2022 | finance.yahoo.comVectivBio Announces Pricing of $30 Million Public Offering of Ordinary SharesJune 14, 2022 | seekingalpha.comVectivBio launches public offering of shares, ~$20M private placement transactionJune 14, 2022 | finance.yahoo.comVectivBio Announces Launch of Public Offering of Ordinary SharesJune 9, 2022 | finance.yahoo.comVectivBio Publishes Invitation to the Annual General MeetingJune 2, 2022 | finance.yahoo.comVectivBio Announces First Two Patients Dosed in Phase 2 STARGAZE Study of Apraglutide for the Treatment of Acute Graft-versus-Host DiseaseMay 9, 2022 | finance.yahoo.comVectivBio to Participate at the Bank of America 2022 Healthcare ConferenceApril 21, 2022 | apnews.comVectivBio Appoints Patrick Malloy as Senior Vice President, Investor Relations & Strategic CommunicationsApril 21, 2022 | finance.yahoo.comVectivBio Appoints Patrick Malloy as Senior Vice President, Investor Relations & Strategic CommunicationsApril 7, 2022 | finance.yahoo.comVectivBio Reports Full Year 2021 Financial Results and Provides Business UpdateApril 4, 2022 | benzinga.comHow To Attend VectivBio Holding Q4 2021 Earnings Conference CallMarch 30, 2022 | seekingalpha.comVectivBio in licensing deal worth up to $200M for GLP-2 analog apraglutideMarch 30, 2022 | marketwatch.comVectivBio in Japan Licensing Agreement With Asahi Kasei PharmaMarch 29, 2022 | finance.yahoo.comVectivBio Presents New Clinical Data Supporting Apraglutide for Treatment of Short Bowel Syndrome with Intestinal Failure (SBS-IF) Patients Who Have Renal Dysfunction at the 2022 American Society of Parenteral and Enteral Nutrition ConferenceMarch 23, 2022 | finance.yahoo.comVectivBio Presents Preclinical Data Supporting Apraglutide for Treatment of Acute Graft-Versus-Host Disease at the 48th Annual Meeting of the European Society for Blood and Marrow TransplantationFebruary 8, 2022 | finance.yahoo.comVectivBio to Present at the SVB Leerink 11th Annual Global Healthcare ConferenceFebruary 4, 2022 | msn.com6 Underperforming IPO Stocks To Buy On The DipJanuary 5, 2022 | finance.yahoo.comWhat Percentage Of VectivBio Holding AG (NASDAQ:VECT) Shares Do Insiders Own?November 10, 2021 | finance.yahoo.comVectivBio Announces Third Quarter 2021 Business UpdateSee More Headlines Industry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:VECT CUSIPN/A CIK1836379 Webvectivbio.com Phone41 61 551 30 3FaxN/AEmployeesN/AYear FoundedN/ACompany Calendar Today7/07/2022Next Earnings (Estimated)7/07/2022Fiscal Year End12/31/2022Price Target and Rating Average Stock Price Forecast$23.00 High Stock Price Forecast$23.00 Low Stock Price Forecast$23.00 Forecasted Upside/Downside+286.2%Consensus RatingBuy Rating Score (0-4)3 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio6.41 Quick Ratio6.41 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.41 per share Price / Book1.75Miscellaneous Outstanding Shares34,015,000Free FloatN/AMarket Cap$202.58 million OptionableNot Optionable Beta-0.61 VectivBio Frequently Asked Questions Should I buy or sell VectivBio stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for VectivBio in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" VectivBio stock. View analyst ratings for VectivBio or view top-rated stocks. What is VectivBio's stock price forecast for 2022? 1 brokers have issued 12 month price targets for VectivBio's stock. Their VECT stock forecasts range from $23.00 to $23.00. On average, they expect VectivBio's stock price to reach $23.00 in the next year. This suggests a possible upside of 286.2% from the stock's current price. View analysts' price targets for VectivBio or view top-rated stocks among Wall Street analysts. How has VectivBio's stock price performed in 2022? VectivBio's stock was trading at $4.91 at the beginning of 2022. Since then, VECT stock has increased by 21.3% and is now trading at $5.9557. View the best growth stocks for 2022 here. When is VectivBio's next earnings date? VectivBio is scheduled to release its next quarterly earnings announcement on Thursday, July 7th 2022. View our earnings forecast for VectivBio. Who are VectivBio's key executives? VectivBio's management team includes the following people: Dr. Luca Santarelli M.D., Founder, CEO & Director (Age 53)Ms. Claudia D'Augusta Ph.D., Chief Financial Officer (Age 52)Dr. Christian Meyer M.D., Ph.D., Chief Operating Officer (Age 55)Dr. Alain Bernard Ph.D., Chief Technology Officer (Age 65)Mr. Patrick Malloy, Sr. VP of Investor Relations & Strategic CommunicationsMr. Scott Applebaum, Chief Legal Officer & Corp. Sec. (Age 55)Mr. Michael Steininger, Sr. VP & Head of HRMr. Kevin Harris M.B.A., Chief Commercial Officer (Age 51)Dr. Sarah Holland Ph.D., Chief Bus. Officer (Age 59)Dr. Omar Khwaja M.D., Ph.D., Chief Medical Officer (Age 51) Who are some of VectivBio's key competitors? Some companies that are related to VectivBio include iTeos Therapeutics (ITOS), Instil Bio (TIL), Agenus (AGEN), Sangamo Therapeutics (SGMO), Coherus BioSciences (CHRS), Osiris Therapeutics (OSIR), NanoString Technologies (NSTG), Cullinan Oncology (CGEM), Immatics (IMTX), Ocugen (OCGN), Vaxart (VXRT), Century Therapeutics (IPSC), Inhibrx (INBX), Immunovant (IMVT) and Monte Rosa Therapeutics (GLUE). View all of VECT's competitors. When did VectivBio IPO? (VECT) raised $128 million in an IPO on Friday, April 9th 2021. The company issued 7,500,000 shares at $16.00-$18.00 per share. BofA Securities, SVB Leerink and Credit Suisse served as the underwriters for the IPO and LifeSci Capital was co-manager. What is VectivBio's stock symbol? VectivBio trades on the NASDAQ under the ticker symbol "VECT." How do I buy shares of VectivBio? Shares of VECT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is VectivBio's stock price today? One share of VECT stock can currently be purchased for approximately $5.96. How much money does VectivBio make? VectivBio (NASDAQ:VECT) has a market capitalization of $202.58 million. How can I contact VectivBio? The official website for VectivBio is vectivbio.com. The company can be reached via phone at 41 61 551 30 3 or via email at ir@vectivbio.com. This page (NASDAQ:VECT) was last updated on 7/7/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here
